July 20, 2015, Wellesley, MA. & Reston, VA. Outcome Capital (outcomecapital.wpengine.com) today announced that Craig A. Steger has joined the firm as a Senior Advisor for its rapidly growing Boston area-based life sciences practice, bolstering the firm’s expertise in the molecular diagnostics and biotechnology sectors.
A business leader with extensive global experience, Steger has been part of several successful molecular diagnostic start-ups through their eventual acquisitions. Steger joins Outcome from Forge 4ward, a life science and diagnostic consulting firm, where he has been working with clients to develop their commercial strategy and build value both in the US and globally. He has held various executive positions from start-up companies through large, well-established international corporations. His success in building commercially viable and sustainable enterprises has led to the completion of several successful acquisitions over the past several years including Caliper Life Sciences, HandyLab and BioHelix. Key successes also include developing and launching new businesses at Fisher Healthcare and Becton Dickinson. Steger’s scientific background and business experience spans sales, marketing, business development, licensing, strategic partnerships and operations. Steger holds a Bachelor of Science from the University of Wisconsin and a Master of Science from Yale University.
“I love helping life science companies grow, and at Outcome I am able to accomplish this using the firm’s unique market-driven strategy approach that aligns businesses with sector dynamics – an approach that resonates well with both my experience and passion,” said Steger. “It’s never just about a financial transaction – we’re in the trenches with our clients getting a deep understanding of their value proposition before identifying the most strategic path forward toward optimal value creation.”
Dr. Oded Ben-Joseph, Managing Director at Outcome Capital commented: “As the life sciences market has matured, we have experienced considerable growth from mid- to growth-stage companies looking for sound strategies for mergers and acquisitions, private debt and equity placement, and other strategic and corporate finance advisory services. Unique among investment banking firms, our strategic approach to value enhancement relies on significant corporate and operational experience, and Craig’s experience nicely complements our growing life sciences team and bolsters our expertise in molecular diagnostics and biotechnology.”
About Outcome Capital
Outcome Capital is a unique investment banking firm that provides middle-market growth companies in the life sciences, healthcare services and technology markets with a value-added client-centric approach to merger, acquisition and corporate finance advisory services. The firm utilizes its proven approach to value enhancement by assisting boards and management teams in navigating both the financial and strategic markets and in implementing the best path for success. Outcome Capital’s strength stems from its unique ability to draw on its wide range of operational, strategic and private equity experience, its expertise across the value building life-cycle and its broad industry relationships. The professionals at Outcome Capital take pride in their ability to help their clients to make well-informed strategic decisions and recognize the full value created by their vision. For more information, visit: outcomecapital.wpengine.com.
Outcome Capital Named Top 10 M&A Consulting Firms December 1, 2022 Outcome Capital leads in Financial Services Review annual listing of 10 companies that are at the forefront of providing Mergers & Acquisitions Consulting services & impacting the marketplace. Read the full article here:Read More
Outcome Capital Life Science Market Pulse February 2023 Click to view our LifeSciences Pulse NewsletterDownload
Would you like to learn more about working with Outcome Capital or discuss your specific needs?